Related Experiment Video

Updated: Jun 4, 2026

Comparative Strategies for Ubiquitination Detection in Mammalian Cell Lysates Using SMAD2/SMURF2 as a Model
09:00

Comparative Strategies for Ubiquitination Detection in Mammalian Cell Lysates Using SMAD2/SMURF2 as a Model

Published on: April 17, 2026

CYLD: a deubiquitination enzyme with multiple roles in cancer

Ramin Massoumi1

  • 1Department of Laboratory Medicine, Molecular Tumor Pathology, Lund University, Malmö, Sweden. ramin.massoumi@med.lu.se

Future Oncology (London, England)
|February 25, 2011
PubMed

Insights

The deubiquitinating enzyme CYLD suppresses tumors by regulating cell survival and proliferation. Its loss of function in cancer highlights its role as a tumor suppressor gene, offering potential therapeutic targets.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Ubiquitination is a key post-translational modification regulating cellular processes.
  • Dysregulation of the ubiquitin system is implicated in various diseases, including cancer.
  • CYLD, a deubiquitinating enzyme, removes specific ubiquitin chains and influences cell fate.

Purpose of the Study:

  • To review recent findings on the role of CYLD in human cancers.
  • To explore how CYLD functions as a tumor suppressor.
  • To identify CYLD-mediated pathways for cancer diagnosis and therapy.

Main Methods:

  • Literature review of recent advances linking CYLD to cancer.
  • Analysis of CYLD's function in regulating cell survival and proliferation.
  • Examination of CYLD's tumor suppressor activity and mechanisms of expression loss.

Main Results:

  • CYLD acts as a tumor suppressor gene, with its loss observed in various human cancers.
  • CYLD expression can be downregulated via genetic mutations, RNA regulation, or protein modifications.
  • CYLD's deubiquitinating activity impacts cell survival and proliferation pathways relevant to cancer.

Conclusions:

  • CYLD plays a critical role in preventing cancer development.
  • Understanding CYLD-mediated signaling pathways is crucial for developing novel cancer therapies.
  • Targeting CYLD or its pathways may offer new diagnostic and therapeutic strategies for cancer.

More Related Videos

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology10:25

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

Method for Measuring the Activity of Deubiquitinating Enzymes in Cell Lines and Tissue Samples09:45

Method for Measuring the Activity of Deubiquitinating Enzymes in Cell Lines and Tissue Samples

Published on: May 10, 2015

Related Concept Videos

Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...